| 6I3U: reference: Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models., Toledo-Sherman L, Breccia P, Cachope R, Bate JR, Angulo-Herrera I, Wishart G, Matthews KL, Martin SL, Cox HC, McAllister G, Penrose SD, Vater H, Esmieu W, Van de Poel A, Van de Bospoort R, Strijbosch A, Lamers M, Leonard P, Jarvis RE, Blackaby W, Barnes K, Eznarriaga M, Dowler S, Smith GD, Fischer DF, Lazari O, Yates D, Rose M, Jang SW, Munoz-Sanjuan I, Dominguez C, J Med Chem. 2019 Mar 19. doi: 10.1021/acs.jmedchem.8b01819. PMID: 30840447 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).